Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Atossa Therapeutics and keeping the price target at $4.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy’s rating is based on the promising potential of Atossa Therapeutics’ oral endoxifen, particularly in the treatment of metastatic breast cancer (mBC). The recent FDA approval of Eli Lilly’s imlunestrant highlights the demand for new therapeutic options in this space, and Atossa’s endoxifen shows favorable comparisons in terms of progression-free survival (PFS). In prior studies, endoxifen demonstrated a PFS of 7.2 months, which is promising compared to other treatments.
Moreover, endoxifen offers a distinct advantage as it is mutation-agnostic and does not require metabolic activation, unlike tamoxifen. This characteristic ensures consistent plasma exposure and potentially restores receptor blockade in resistant tumors. Atossa’s ongoing research, including molecular modeling and in vitro work, further supports endoxifen’s potential efficacy in stabilizing the inactive form of the estrogen receptor, making it a compelling candidate for future clinical trials and regulatory filings.
McCarthy covers the Healthcare sector, focusing on stocks such as OS Therapies Incorporated, Atossa Therapeutics, and SCYNEXIS. According to TipRanks, McCarthy has an average return of -17.7% and a 31.66% success rate on recommended stocks.
In another report released on September 21, Ascendiant also maintained a Buy rating on the stock with a $7.75 price target.